GlassScriptPhysician profile
Alexander Gaitanis
NPI 1114937844
$3,185.96
in general payments reported to CMS, 2019-2025
36 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $668 · 2021: $181 · 2022: $25.78 · 2024: $340 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $388.90 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $288.69 | 2019-2025 | Calquence |
| Pfizer INC. | $235.83 | 2019-2025 | |
| Genentech USA, INC. | $225.71 | 2019-2024 | Lunsumio |
| Janssen Biotech, INC. | $179.33 | 2019-2025 | Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $173.88 | 2019-2024 | Enhertu |
| Tesaro, INC. | $162.24 | 2019 | |
| Amgen INC. | $146.02 | 2019-2020 | |
| Eisai INC. | $145.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $141.87 | 2019-2024 | Keytruda |
| Abbvie INC. | $123.52 | 2019-2024 | |
| Incyte Corporation | $99.71 | 2019-2024 | Jakafi |
| Seagen INC. | $93.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $84.88 | 2024-2025 | |
| Astellas Pharma US INC | $82.35 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $67.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.99 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $62.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.62 | 2019-2022 | |
| Elekta, INC. | $38.71 | 2020 | |
| Sobi, INC | $36.78 | 2024-2025 | |
| Lilly USA, LLC | $32.92 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $25.41 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.95 | 2019 | |
| Tersera Therapeutics LLC | $22.75 | 2020 | |
| Beigene USA, INC. | $19.70 | 2024 | Tevimbra |
| Kite Pharma, INC. | $19.67 | 2021 | |
| Dova Pharmaceuticals | $19.00 | 2020 | |
| Genzyme Corporation | $18.04 | 2019 | |
| Tactile Systems Technology INC | $17.17 | 2020 | |
| Advanced Accelerator Applications | $16.86 | 2019 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Glaxosmithkline, LLC. | $15.74 | 2021 | |
| Spectrum Pharmaceuticals INC. | $15.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.18 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Gaitanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.